Quarterly report · Q2
3055.TEDINET S100PK8H
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥129.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥248.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥122.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥759m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.1bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.7bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥1.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥140.6bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥136.9bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥137.0bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥83.9bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥81.3bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥56.6bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥55.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥55.4bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥21.4bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥21.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.4bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥22.6bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.4bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.1bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥122m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥224m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥633m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥849m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥648m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥62.94 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.94 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.44 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥52.06 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.17 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 40.3% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.5% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2022-04-01 → 2022-09-30 | ¥1.6bn |
| Otherother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥30m |
| Otherother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.6bn |
| Otherother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥910m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥6m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥40m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥848m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥217m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥631m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥20m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥33.0bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥32.7bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥251m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥777m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥172m |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥92.3bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥87.7bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4.5bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥347m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥136.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥129.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥7.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥2.2bn |
| Otherother segments | revenue | 2021-04-01 → 2021-09-30 | ¥1.0bn |
| Otherother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥30m |
| Otherother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥991m |
| Otherother segments | segment profit | 2021-04-01 → 2021-09-30 | ¥345m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥7m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥40m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥675m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥217m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥457m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥28m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥30.7bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥30.4bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥237m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥572m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥5m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥157m |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥87.2bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥82.8bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.5bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥113m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥128.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥122.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥1.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 550
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 2678000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.1219 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 1408000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0641 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 1297000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0591 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 1176000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0535 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 896000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0408 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 808000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0368 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 584000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0266 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 546000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0249 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 468000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0213 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 457000 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0208 | |
| Number of shares held | CurrentQuarterInstant | 10322000 | |
| Shareholding ratio | CurrentQuarterInstant | 0.4699 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 2431800 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 21953300 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 219533 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 14900 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 24400000 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 219533 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 2431800 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 2431800 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0997 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 2431800 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 2431800 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0997 | |
| Cash and deposits | Prior1YearInstant | 21091000000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 21404000000 | JPY |
| Notes and accounts receivable trade | Prior1YearInstant | 52740000000 | JPY |
| Notes and accounts receivable trade | CurrentQuarterInstant | 55619000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 15974000000 | JPY |
| Merchandise and finished goods | CurrentQuarterInstant | 17012000000 | JPY |
| Work in process | Prior1YearInstant | 3000000 | JPY |
| Work in process | CurrentQuarterInstant | 12000000 | JPY |
| Other ca | Prior1YearInstant | 7706000000 | JPY |
| Other ca | CurrentQuarterInstant | 7121000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |